PDF
Corrigendum | Open Access
Hai-han Liao, Jin-xiu Zhu, Hong Feng, Jian Ni, Nan Zhang, Si Chen, Huang-jun Liu, Zheng Yang, Wei Deng, Qi-Zhu Tang, "Corrigendum to “Myricetin Possesses Potential Protective Effects on Diabetic Cardiomyopathy through Inhibiting IκBα/NFκB and Enhancing Nrf2/HO-1”", Oxidative Medicine and Cellular Longevity, vol. 2021, Article ID 9812928, 2 pages, 2021. https://doi.org/10.1155/2021/9812928
Corrigendum to “Myricetin Possesses Potential Protective Effects on Diabetic Cardiomyopathy through Inhibiting IκBα/NFκB and Enhancing Nrf2/HO-1”
Hai-han Liao
,1,2,3 Jin-xiu Zhu,1,2,3 Hong Feng,4 Jian Ni,1,2,3 Nan Zhang,1,2,3 Si Chen,2,3 Huang-jun Liu,1,2,3 Zheng Yang,1,2,3 Wei Deng,1,2,3 and Qi-Zhu Tang1,2,31Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, China
2Cardiovascular Research Institute of Wuhan University, Wuhan, China
3Hubei Key Laboratory of Cardiology, Wuhan, China
4Department of Gerontology, Renmin Hospital of Wuhan University, Wuhan 430060, China
In the article titled “Myricetin possesses potential protective effects on diabetic cardiomyopathy through inhibiting IκBα/NFκB and enhancing Nrf2/HO-1” [1], an error was identified in Figure 8(b) where the same original blots were mistakenly used for T-Nrf2 and HO-1 when preparing the image. The authors have provided the correct images for T-Nrf2 and HO-1 and the revised Figure 8 is as below:
(a)
(b)
(c)
(d)
(e)
References
- H.-h. Liao, J.-x. Zhu, H. Feng et al., “Myricetin possesses potential protective effects on diabetic cardiomyopathy through inhibiting IκBα/NFκB and enhancing Nrf2/HO-1,” Oxidative Medicine and Cellular Longevity, vol. 2017, Article ID 8370593, 14 pages, 2017. View at: Publisher Site | Google Scholar
Copyright
Copyright © 2021 Hai-han Liao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
